title: Effect of low-dose amiodarone and magnesium combination on atrial fibrillation after coronary artery surgery.
abstract: BACKGROUND
  To evaluate whether postoperative administration of intravenous low-dose amiodarone and magnesium sulfate (MgSO(4)) combination would reduce the incidence of atrial fibrillation following coronary artery bypass grafting (CABG) in normomagnesemic high-risk patients for postoperative atrial fibrillation (POAF).
  
  
  METHODS
  A total of 136 patients undergoing elective CABG and had > or =3 risk factors for POAF were prospectively randomized to one of three groups, to receive a single dose of amiodarone (5 mg/kg) and MgSO(4) (1.5 g) (combination group, n = 44), or an equal dose of amiodarone (amiodarone group, n = 44) or equal volumes of saline (control group, n = 48) at early postoperative period. Continuous electrocardiographic (ECG) monitoring was performed for the first 48 hours and an ECG was recorded every 8 hours later. POAF longer than 30 minutes or for any length requiring treatment, and the drug-related side effects were recorded.
  
  
  RESULTS
  The study population showed a homogeneous distribution regarding risk factors for POAF and there was no significant difference in patient characteristics, echocardiographic variables, or operative variables among three groups. POAF developed in 4 patients in combination group, in 16 patients in amiodarone group and in 16 patients in control group, representing a 24% relative risk reduction between the combination group and control group (p = 0.023). No statistically significant difference regarding incidence of POAF was observed between amiodarone and control groups.
  
  
  CONCLUSIONS
  Combined prophylactic therapy with amiodarone and MgSO(4) at the early postoperative period without a maintenance phase is an effective, simple, well-tolerated, and possibly cost-effective regimen to prevent POAF in normomagnesemic, high-risk patients.
authors.affiliation: Department of Cardiovascular Surgery, Türkiye Yuksek Ihtisas Hospital, Anakara, Turkey. kerimcagli@hotmail.com
authors.forename: Kerim
authors.initials: K
authors.lastname: Cagli
authors.forename: Ozcan
authors.initials: O
authors.lastname: Ozeke
authors.forename: Kumral
authors.initials: K
authors.lastname: Ergun
authors.forename: Baran
authors.initials: B
authors.lastname: Budak
authors.forename: Ertan
authors.initials: E
authors.lastname: Demirtas
authors.forename: Cemal Levent
authors.initials: CL
authors.lastname: Birincioglu
authors.forename: Mustafa
authors.initials: M
authors.lastname: Pac
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000008:administration & dosage* / Q000009:adverse effects; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000209:etiology / Q000517:prevention & control*; D001026:Coronary Artery Bypass / Q000009:adverse effects; D003324:Coronary Artery Disease / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D006801:Humans; D015994:Incidence; D007275:Injections, Intravenous; D008278:Magnesium Sulfate / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012107:Research Design; D012307:Risk Factors; D016896:Treatment Outcome; D014421:Turkey
chemical_list: D000889:Anti-Arrhythmia Agents; D008278:Magnesium Sulfate; D000638:Amiodarone